Idioma:

Male Sexual Dysfunction Associated With Antiretroviral Therapy

Colson, Amy E ; Keller, Marla J ; Sax, Paul E ; Pettus, Parker T ; Platt, Richard ; Choo, Peter W

Journal of acquired immune deficiency syndromes (1999), 2002-05, Vol.30 (1), p.27-32 [Periódico revisado por pares]

Hagerstown, MD: Lippincott Williams & Wilkins, Inc

Texto completo disponível

Citações Citado por

Enviar para

Título:
Male Sexual Dysfunction Associated With Antiretroviral Therapy
Autor: Colson, Amy E ; Keller, Marla J ; Sax, Paul E ; Pettus, Parker T ; Platt, Richard ; Choo, Peter W
Assuntos: Adolescent ; Adult ; Aged ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antiviral agents ; Biological and medical sciences ; Cohort Studies ; Drug therapy ; Erectile Dysfunction - chemically induced ; Health care ; HIV Infections - drug therapy ; HIV Protease Inhibitors - adverse effects ; HIV-1 ; Humans ; Indinavir - adverse effects ; Male ; Managed Care Programs ; Medical sciences ; Men ; Middle Aged ; Nelfinavir - adverse effects ; New England ; Pharmacology. Drug treatments ; Retrospective Studies ; Ritonavir - adverse effects ; Saquinavir - adverse effects ; Sexual behavior
É parte de: Journal of acquired immune deficiency syndromes (1999), 2002-05, Vol.30 (1), p.27-32
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Descrição: To determine whether treatment with protease inhibitors (PIs) is associated with male sexual dysfunction, we conducted a retrospective, cohort study of 254 adult male PI recipients who received care from the staff-model division of a large managed care organization in New England between 1993 and 1998. After a median of 5.0 years of observation, 80 incident cases of sexual dysfunction were observed. Relative to unexposed individuals, the rate of sexual dysfunction adjusted for confounding was most elevated with use of ritonavir (hazard ratio [HR], 2.83; 95% confidence interval [CI], 1.34-5.97; p = .006) followed by indinavir (HR, 1.69; 95% CI, 0.84-3.37; p = .14), nelfinavir (HR, 1.53; 95% CI, 0.66-3.54; p = .32) and saquinavir (HR, 1.25; 95% CI, 0.53-2.96; p = .60). We conclude that PIs, especially ritonavir, appear to increase the risk of sexual dysfunction.
Editor: Hagerstown, MD: Lippincott Williams & Wilkins, Inc
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Male Sexual Dysfunction Associated With Antiretroviral Therapy

Colson, Amy E ; Keller, Marla J ; Sax, Paul E ; Pettus, Parker T ; Platt, Richard ; Choo, Peter W

Hagerstown, MD: Lippincott Williams & Wilkins, Inc

Buscando em bases de dados remotas. Favor aguardar.